Investors focused on the Medical space have likely heard of Lannett Co , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Lannett Co is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. LCI is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for LCI's full-year earnings has moved 2.55% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Our latest available data shows that LCI has returned about 57.26% since the start of the calendar year. At the same time, Medical stocks have gained an average of 3.79%. As we can see, Lannett Co is performing better than its sector in the calendar year.

Looking more specifically, LCI belongs to the Medical - Drugs industry, a group that includes 175 individual stocks and currently sits at #65 in the Zacks Industry Rank. On average, this group has gained an average of 9.23% so far this year, meaning that LCI is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on LCI as it attempts to continue its solid performance.